Answers are grounded in this paper and cite their sources.
TUMOR MARKERS ARE circulating factors that are measurable in biologic fluids of patients with cancer and serve as a marker of the disease state. In 1965 Gold and Freedman demonstrated that a fetal antigen (carcinoembryonic antigen, CEA) was present in extracts of tumors from the gastrointestinal tract and fetal gut tissue but not in extracts of adult intestinal tissue. Subsequently this antigen was detected in the circulation of patients with gastrointestinal cancer, but not in the circulation of patients with nonmalignant conditions.1 Despite these auspicious beginnings and the fact that radioimmunoassay, enzyme-linked immunoassay, and other immunologic assays can detect minute amounts of tumor markers accurately and reproducibly, tumor markers have not been as useful in the clinical practice of oncology as the initial studies suggested they would be.
No takes yet. Share an insight, caveat, or question.
Jeffrey A. Norton (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: